DBV Technologies S.A. (NASDAQ:DBVT)‘s stock had its “buy” rating reiterated by research analysts at Jefferies Group LLC in a research note issued on Thursday.

Several other research analysts have also issued reports on the company. Zacks Investment Research upgraded DBV Technologies from a “hold” rating to a “buy” rating and set a $50.00 price objective for the company in a research note on Tuesday. Leerink Swann increased their price objective on DBV Technologies from $54.00 to $60.00 and gave the stock an “outperform” rating in a research note on Friday, August 25th. BidaskClub upgraded DBV Technologies from a “hold” rating to a “buy” rating in a research note on Tuesday, August 22nd. ValuEngine upgraded DBV Technologies from a “sell” rating to a “hold” rating in a research note on Thursday, July 13th. Finally, Morgan Stanley reiterated an “overweight” rating on shares of DBV Technologies in a research note on Monday, July 10th. Two research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. DBV Technologies has a consensus rating of “Buy” and a consensus price target of $50.00.

DBV Technologies (NASDAQ:DBVT) opened at 44.62 on Thursday. The stock’s 50 day moving average is $43.90 and its 200 day moving average is $37.21. The company’s market cap is $2.05 billion. DBV Technologies has a 52-week low of $31.87 and a 52-week high of $46.33.

ILLEGAL ACTIVITY NOTICE: “DBV Technologies S.A. (DBVT) Rating Reiterated by Jefferies Group LLC” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://www.thecerbatgem.com/2017/09/02/dbv-technologies-s-a-dbvt-rating-reiterated-by-jefferies-group-llc.html.

Several hedge funds have recently made changes to their positions in the stock. Janus Henderson Group PLC acquired a new stake in shares of DBV Technologies during the second quarter worth $90,724,000. Jennison Associates LLC raised its stake in shares of DBV Technologies by 86.4% in the second quarter. Jennison Associates LLC now owns 1,002,067 shares of the company’s stock worth $35,784,000 after buying an additional 464,341 shares during the period. Alliancebernstein L.P. raised its stake in shares of DBV Technologies by 21.1% in the first quarter. Alliancebernstein L.P. now owns 996,535 shares of the company’s stock worth $35,098,000 after buying an additional 173,798 shares during the period. Morgan Stanley raised its stake in shares of DBV Technologies by 89.9% in the first quarter. Morgan Stanley now owns 249,988 shares of the company’s stock worth $8,805,000 after buying an additional 118,317 shares during the period. Finally, Sectoral Asset Management Inc raised its stake in shares of DBV Technologies by 34.2% in the second quarter. Sectoral Asset Management Inc now owns 179,152 shares of the company’s stock worth $6,398,000 after buying an additional 45,653 shares during the period. Institutional investors own 45.52% of the company’s stock.

About DBV Technologies

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.

Analyst Recommendations for DBV Technologies (NASDAQ:DBVT)

Receive News & Stock Ratings for DBV Technologies S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies S.A. and related stocks with our FREE daily email newsletter.